Where Asymmetric Dimethylarginine (ADMA) is reported
Also listed as: Asymmetric dimethylarginine (ADMA); NO synthase inhibitor
| Condition | Direction | Compared against | Associated symptoms | Source |
|---|---|---|---|---|
| Hypertension | ↕ inconsistent | normotension group | disaster-related hypertension after Great East Japan Earthquake | Shiraishi et al. 2016 |
| Long COVID | ↑ elevated | healthy controls | Reduced NO bioavailability | Thomas et al. 2024 |
Frequently asked questions
In which conditions is Asymmetric Dimethylarginine (ADMA) altered?
In the OSMF atlas Asymmetric Dimethylarginine (ADMA) is reported in Hypertension, Long COVID. It is elevated in 1, mixed in 1 across 2 entries.
Does Asymmetric Dimethylarginine (ADMA) point to one specific diagnosis?
No. Because Asymmetric Dimethylarginine (ADMA) changes in several conditions (Hypertension, Long COVID), an abnormal result cannot identify which condition, if any, is present. It must be interpreted with symptoms, history and other tests.
What is the LOINC code for Asymmetric Dimethylarginine (ADMA)?
Entries in this atlas use LOINC 74363-3. LOINC codes identify the laboratory observation so results can be compared across systems.
Is one abnormal Asymmetric Dimethylarginine (ADMA) result diagnostic?
No single biomarker result is diagnostic of any of these conditions. Findings reflect group averages from published cohorts with substantial overlap between patients and controls.
Cite this page
Disclaimer: Educational synthesis of peer-reviewed research; not medical advice. Findings are group-level and vary with study design. Discuss any result with a qualified clinician.